

## DiabetOmics launches manufacturing facility in Hyderabad

05 March 2018 | News

**The company will utilize this facility to commercialize world's first highly-accurate non-invasive diabetes tests.**



DiabetOmics, a global medical diagnostics company that is developing the world's first patented non-invasive, saliva-based diabetes monitoring test has opened its first manufacturing facility in Hyderabad. **Hon'ble Minister for IT, Municipal Administration & Urban Development, Industries & Commerce, Public Enterprises, Shri. K.T.Rama Rao** inaugurated this facility recently. DiabetOmics will utilize this facility to commercialize their highly accurate, easy-to-use, bluetooth-enabled and non-invasive diabetes point of care (POC) tests and maternal health tests in India and around the world. Ventureast invested about 4 million in DiabetOmics in 2015.

This new facility, which is situated in a three acre plot in Muppireddipally will directly employ about 100-120 people. The overall capacity of the plant will be to produce 8-10 million test strips a year and 10,000 to 15,000 assembled readers to begin with. The company has completed construction of their world-class manufacturing plant and the technology transfer from USA. The commercial production is expected to begin in the next quarter this year and will target the Indian and European markets.

The global burden of diabetics is over 375 million, with India (72 million) and China (109 million) as major epicenters for diabetes. **Dr. Srinivasa Nagalla, CEO of DiabetOmics Inc.**, said "We are pleased to bring these innovative diagnostic tests to the market beginning later part of this year which will be a huge paradigm shift for the patients around the world particularly for emerging countries like India where the affordability of quality care is a major burden for many low income families".

In addition to saliva-based diabetes tests, the company is currently developing point-of-care tests for rapid screening of Type I diabetes and early detection of diabetic kidney and eye complications. Across the world, it has been identified that Preeclampsia is the second leading cause of maternal death and gestational diabetes which is a common prenatal complication affecting 16 percent pregnancies.

**Mr. Venkatadri Bobba, Director- DiabetOmics & General Partner, Ventureast** said, "DiabetOmics has come a long way from the discovery of the Salivary Glycoproteins as the best biomarkers for Glycemic Index to product and Bluetooth-enabled readers. The new plant will be in full compliance with global regulatory requirements and will showcase high quality and low cost manufacturing capabilities of our highly qualified & well trained staff and the ecosystem enabled by the State of

Telangana. Most importantly, it is gratifying to note that many patients and their families could benefit from our innovations beginning later part of this year.”

***Dr. Varaprasad Reddy, Founder Shantha Biotech and Chairman Diabetomics India*** said, “We are excited that our manufacturing facility has been built, technology transferred, within months of getting the CE Mark (European approvals) and start supplying the products to the needy patients in just about 2 years from the date of laying foundation stone in Feb 2016. We are happy to bring this innovative non-invasive testing which is free of pain and patient friendly to the market.”